G. L. Breschi, F. Demma, P. Morelli, and M. De Francesco, “Brentuximab vedotin in adult patients with HL CD30+ at high risk of relapse or progression following ASCT: a cost-analysis in Italy”, AboutOpen, vol. 8, no. 1, pp. 81–87, Sep. 2021.